WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, depository shares, debt securities and/or warrants in one or more offerings. As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement and the Company is not required to offer the securities in the future pursuant to the registration statement.
Help employers find you! Check out all the jobs and post your resume.
